Royalty Pharma (RPRX) Return on Capital Employed Growth (3y) (2023 - 2026)
Royalty Pharma (RPRX) Return on Capital Employed Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 69,146.49 Bn | 69,146.20 Bn | - | - |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 475.42 Bn | 470.63 Bn | 1.35 Bn | 4,893.00 |
| 5 | Vertex Pharmaceuticals | 123.32 Bn | 116.08 Bn | 2.59 Bn | -494.00 |
| 6 | Regeneron Pharmaceuticals | 69.80 Bn | 61.04 Bn | 3.31 Bn | -649.00 |
| 7 | Belite Bio | 63.28 Bn | 63.28 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.48 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.15 Bn | 38.15 Bn | - | -3,782.00 |
| 10 | Royalty Pharma | 25.82 Bn | 25.21 Bn | - | 470.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 470.00 |
| Dec 31, 2025 | 636.00 |
| Sep 30, 2025 | 268.00 |
| Jun 30, 2025 | 492.00 |
| Mar 31, 2025 | 315.00 |
| Dec 31, 2024 | -54.00 |
| Sep 30, 2024 | -18.00 |
| Jun 30, 2024 | -551.00 |
| Mar 31, 2024 | -349.00 |
| Dec 31, 2023 | -81.00 |
| Sep 30, 2023 | -1,436.00 |